AbbVie Acquires Capstan Therapeutics in $2.1 Billion Deal
On Monday, AbbVie announced a major deal to buy Capstan Therapeutics for up to $2.1 billion in cash. This move boosts AbbVie’s lineup of new treatments, focusing on autoimmune diseases, as its top drug, Humira, loses steam. Capstan brings exciting CAR-T therapies to the table, targeting conditions that affect millions. AbbVie needs fresh options since…